A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.
NYU Langone Health
National Institutes of Health Clinical Center (CC)
Novartis
National Institutes of Health Clinical Center (CC)
Compass Therapeutics
Pliant Therapeutics, Inc.
Nested Therapeutics, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hangzhou Hanx Biopharmaceuticals, Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Genentech, Inc.
Nantes University Hospital
Boehringer Ingelheim
The Netherlands Cancer Institute
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
Diakonos Oncology Corporation
Immatics US, Inc.
Bristol-Myers Squibb
National Cancer Institute (NCI)
Toray Industries, Inc
National Cancer Institute (NCI)
Providence Health & Services
University of Pittsburgh
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
Merck Sharp & Dohme LLC
University Health Network, Toronto
Alliance for Clinical Trials in Oncology
KaliVir Immunotherapeutics
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Iovance Biotherapeutics, Inc.
NRG Oncology
M.D. Anderson Cancer Center
Replimune, Inc.
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Fred Hutchinson Cancer Center
Aulos Bioscience, Inc.
Ipsen
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca